Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

40.73
-0.0900-0.22%
Post-market: 40.730.00000.00%19:30 EDT
Volume:53.73K
Turnover:2.19M
Market Cap:1.04B
PE:- -
High:40.88
Open:40.82
Low:40.53
Close:40.82
52wk High:43.52
52wk Low:28.77
Shares:25.65M
Float Shares:25.65M
Volume Ratio:0.06
T/O Rate:0.21%
Dividend:0.29
Dividend Rate:0.71%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

J&J - Safety Findings Through Week 112 Consistent with Icotyde Profile, no New Safety Signals

THOMSON REUTERS
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals

Dow Jones
·
Oct 02

Novartis Strikes up to $7.8 Billion mRNA Deal with China's Abogen

Reuters
·
Oct 02

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Oct 02

Bristol Myers Squibb Co. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval

Simply Wall St.
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says

MT Newswires Live
·
Oct 02

BMY Terminates Early Leukemia Trial, Trimming One Risky Bet From Its Oncology Pipeline

TIPRANKS
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

AbbVie Says Phase 3 Trials Show Rinvoq Vitiligo Repigmentation Gains Extend to Week 76

Reuters
·
Oct 01

Abbvie - Phase 3 Studies Show Continued Repigmentation with Rinvoq Through Week 76

THOMSON REUTERS
·
Oct 01

Abbvie - Rinvoq Plus NB-Uvb Shows Higher Repigmentation than Rinvoq Alone

THOMSON REUTERS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

AbbVie to Host Third-Quarter 2026 Earnings Call Webcast

Reuters
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01